Search results for: Precision Medicine
Filter search results
Delivering the Triple Win: A Value-Based Approach to Pricing
20 April 2023
…is based on the principle that prices should reflect the value of a new medicine to patients, healthcare systems, and society, versus the current standard of care. Unlike other pricing…
Fishing for Innovative Drugs with the ODRS: Potential Benefits and Challenges
6 February 2023
How can fair pricing systems for medicines that balance both access and innovation be designed? This was the question posed by the inaugural OHE Policy Innovation Prize. This Insight looks…
OHE at AES 2016: Early Access Schemes, Equity Adjusted QALYs, Multi-indication Pricing and Formulary Development
2 August 2016
…pathways have been implemented in the last 15 years to expedite the development/licensing of promising new medicines. The aims of such policies are to provide timely access to medicines for…
Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers
1 June 2022
…prices and price growth for top-selling medicines. Share this: Download publication In recent years, U.S. policymakers have been considering reforms to tackle high and rising prescription drug spending, including unprecedented…
Climate action is health action: OHE’s focus on sustainability
22 July 2025
…fronts: Valuing the health co-benefits of climate mitigation One of our central projects is ECO-CHICA, conducted in partnership with the London School of Hygiene & Tropical Medicine and Shouro Dasgupta,…
Presentations and Posters from ISPOR Europe 2016
24 November 2016
…the conference. This post contains their presentations and posters. Plenary session: Differential Pricing of Medicines in Europe: Implications for Access, Innovation, and Affordability. Moderator: Lou Garrison (University of Washington and OHE)….
Migraine
1 September 1991
…therapeutic research and the NHS. After a prolonged period in which drug therapy for migraine has made little advance, research has produced promising medicines for the effective treatment of acute…
Incentives for New Drugs and Vaccines to Tackle Anti-Microbial Resistance
16 May 2017
…poor countries. Additional ways of rewarding R&D are required. Mechanisms designed to encourage companies to undertake R&D on new medicines are generally characterised as either “push” or “pull” programs. “Pull”…
Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies
30 November 2022
Share this: Download publication Adrian Towse Lotte Steuten An increasingly common strategy for treating many cancers is to utilise several medicines with distinct but complementary mechanisms of action in combination…